Compare SOFI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOFI | PCVX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | SOFI | PCVX |
|---|---|---|
| Price | $20.78 | $56.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | $25.75 | ★ $97.67 |
| AVG Volume (30 Days) | ★ 56.8M | 1.6M |
| Earning Date | 01-30-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $3,583,035,000.00 | N/A |
| Revenue This Year | $29.16 | N/A |
| Revenue Next Year | $20.72 | N/A |
| P/E Ratio | $54.10 | ★ N/A |
| Revenue Growth | ★ 33.95 | N/A |
| 52 Week Low | $8.60 | $27.66 |
| 52 Week High | $32.73 | $91.02 |
| Indicator | SOFI | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 26.23 | 60.94 |
| Support Level | $19.19 | $53.12 |
| Resistance Level | $23.36 | $58.95 |
| Average True Range (ATR) | 1.17 | 3.30 |
| MACD | -0.58 | 0.21 |
| Stochastic Oscillator | 13.47 | 72.06 |
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.